Filing Flows › Neogenomics (NEO) › Q2 2026 › vs Q2 2025
Neogenomics (NEO) Q2 2026 vs Q2 2025 (year over year)
Neogenomics's revenue rose $20.3M (+11%) from $181M in Q2 2025 to $202M in Q2 2026. The biggest changes: Commercial insurance +$7.5M (+26%); Client direct billing +$6.8M (+5%); Medicare and other government +$6.0M (+28%).
Neogenomics, Q2 2026: revenue $202M (+11% year over year), operating margin -4.8%, net earnings $2.2M, operating cash flow $20.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 5.8% | 7.7% | -1.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Client direct billing | $138M | $131M | $6.8M | +5% |
| Commercial insurance | $36.3M | $28.8M | $7.5M | +26% |
| Medicare and other government | $27.4M | $21.4M | $6.0M | +28% |
| Revenue | $202M | $181M | $20.3M | +11% |
| Other income, net | $11.6M | $1.8M | $9.8M | +540% |
| Income tax benefit | $412K | $724K | −$312K | -43% |
| Costs & expenses | $214M | $229M | −$15.3M | -7% |
| Operating costs | $211M | $229M | −$17.5M | -8% |
| Net earnings | $2.2M | −$45.1M | $47.3M | — |
| Cost of revenue | $110M | $104M | $5.7M | +5% |
| Research & development | $10.8M | $9.0M | $1.7M | +19% |
| Sales & marketing | $27.3M | $24.1M | $3.2M | +13% |
| General & admin | $63.6M | $71.7M | −$8.1M | -11% |
| Operating cash sources | $26.7M | −$15.6M | $42.3M | — |
| Depreciation & amortization | $16.2M | $17.3M | −$1.1M | -6% |
| Share-based compensation | $8.2M | $12.2M | −$4.0M | -33% |
| Working capital & other | $6.7M | −$35.9M | $42.6M | — |
| Operating cash flow | $20.0M | $20.3M | −$371K | -2% |
| Free cash flow (OCF − capex) | $11.7M | $14.0M | −$2.3M | -16% |
| Capital expenditures | $8.2M | $6.3M | $1.9M | +30% |
Questions
How much did Neogenomics's revenue grow year over year in Q2 2026?
Neogenomics's revenue rose $20.3M (+11%) from $181M in Q2 2025 to $202M in Q2 2026.
What drove Neogenomics's revenue change in Q2 2026?
Commercial insurance +$7.5M (+26%); Client direct billing +$6.8M (+5%); Medicare and other government +$6.0M (+28%).